Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention-Mechanisms and Pharmacodynamics.
Neuropsychiatric disease and treatment – January 01, 2024
Source: PubMed
Summary
A groundbreaking nasal spray delivers rapid relief from severe depression in hours, not weeks. Esketamine works by targeting brain NMDA receptors, offering hope for those with treatment-resistant depression (TRD). Clinical benefits include swift mood improvement and reduced suicide risk, with studies showing sustained positive outcomes. The treatment's unique pharmacodynamics allow for convenient administration while maintaining strong safety and efficacy profiles.
Abstract
Esketamine nasal spray has emerged as a promising rapid-relief therapy for treatment-resistant depression (TRD) and suicide prevention. This review examines the chemical structure and pharmacodynamics of esketamine, highlighting its primary action on NMDA receptors and additional effects on AMPA receptors, opioid receptors, monoaminergic receptors, and inflammatory pathways. Despite the synergistic mechanisms contributing to its clinical benefits not being fully understood, future studies are essential to refine our understanding and optimize clinical use. Clinical research indicates that esketamine effectively alleviates depressive symptoms and prevents suicidal behavior in TRD patients, demonstrating good safety and efficacy over extended periods. Specifically, multiple randomized controlled trials have shown that esketamine reduces depressive symptoms within hours and maintains these benefits over several weeks, with a favorable safety profile and minimal side effects observed in long-term use. The approval of esketamine for TRD has significant implications for healthcare practices and policies, offering a new therapeutic option that addresses the urgent needs of patients with severe depression.